April 30, 2026 4:36pm

Markets to new highs in more than 5 years rising even after disappointing inflation data

After rolling 6 red negative sector closes and 3 green positive over past 9 sessions

Earnings: Alnylam Pharmaceuticals (ALNY); Q1/26 net loss of -$205.991 M or -$1.55 diluted per share, versus Q1/25 of -$18,251 M or -0.14 per share, revenue of $1,17 B versus Q1/25 of $594.1 M, from Q1 2025. and cash of $3 B with a runway until 2030 +

RMi collects, curates, interprets and disseminates cell and gene therapy sector (C&GT) fact-based news, trustable and verified intel of share pricing data bridging the gap to an investment decision

Never leave a retail investor uninformed!  It’s not always time to buy or sell; but it is time to KNOW why!

News: uniQure N.V. (QURE+$3.22or +19.25% to $19.95) held a Pre-Submission Meeting with the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) and plans to submit a Marketing Authorization Application (MAA) for AMT-130 for the treatment of Huntington’s disease in Q326. In addition to the continued engagement with the MHRA, QURE has been granted a Type B meeting with the FDA in the Q2/26. QURE also expects to discuss key elements of a potential P3 trial design and to receive feedback on the proposed statistical analysis plan for the 4-year analysis expected in Q3/26.

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence!  I’m NOT at all writing a doom-and-gloom predictions.  I am more frequently right than consequentially wrong; thus, mostly EARLY in my prognostications!

Thursday’s RMi Pre-opening: None, after multiple red/negative closes, it was inevitable for an upside “drift”

Wednesday’s RMi Closing Bell: Ravished by headlines … https://www.regmedinvestors.com/articles/14400   

 

I chose to speak-up when many analysts, brokers and commentators have shut-up!

 

What happened and some of the whys with the numbers behind

… it’s NOT always about BUYs/SELLs … it’s about knowing when and what!

 

Thursday: The Dow closed UP +790.33 points or +1.62%, the S&P closed UP +73.05 points or +1.02% while the Nasdaq closed UP +219.073 points or +0.89%

  • Theme of the session: strong tech earnings

Thursday (my) 40-company covered sector’s advance/decline line opened positive with 25 incliner, 11 decliners and 4 flats, ending with a positive close of 31 incliners, 6 decliners and 3 flats

  • Sector earnings have begun, with cash positions <so far>to 2028

Henry’omics: We need to more than consider the economic/political environment to comprehend the cause and effect of the macro versus micro data affecting “our” universe of cell and gene therapy (C&GT) sector

  •  PCE, core personal consumption expenditures price index, which excludes food and energy, accelerated a seasonally adjusted 0.3% for the month, pushing the 12-month inflation rate to 3.2%. Volatile gas and groceries components saw higher readings, with the monthly gain at 0.7% and the annual rate hitting 3.5%, also in line with forecasts.
  • GDP, gross domestic product rose at a 2% annualized pace in the period. While that was an increase from 0.5% in Q4/25, it was below the 2.2% estimate.

The CBOE Fear (VIX) index, Thursday closed at 16.96, after Wednesday’s 18.50, Tuesday’s 17.80, Monday’s 18.02, Friday’s 18.70 and last Thursday’s 19.29

Metrics: Thursday …

  • The RUT was up+60.40 points or +2.20%,
  • The XLV was up+3.15 points or +2.21%,
  • The NBI was up +109.06 points or +1.90%;
  • The XBI was up +2.43 points or +1.89%
  • The IWM was up +5.89 or +2.16%;
  • The IBB was up +3.31 points or +2%,
  • The VIX was down -1.85 points or -9.83% at to 16.96
  • The SPX was up +73.07 or +1.02% to 7,209.02

 

Q2/26 – 1 holiday, 1 neutral, 10 negative and 9 positive closes

  • Q1 -March – 9 positive and 13 negative closes
  • February – 1 holiday, 8 negative and 11 positive sessions
  • January – 2 holidays, 2 neutral, 9 negative and 9 positive closes

 

Thursday Closing UP (10 of 31) 

  • Alnylam Pharmaceuticals (ALNY +$8.30 after Wednesday’s -$0.92 after Tuesday’s -$6.40 after Monday’s +$2.97),
  • Vertex (VRTX +$4.14 after Wednesday’s -$6.90 after Tuesday’s +$4.13 after Monday’s -$4.49),
  • uniQure NV (QURE +$3.22 after Wednesday’s -$1.32 after Tuesday’s +$0.15),
  • Arrowhead Pharmaceuticals (ARWR +$2.95 After Wednesday’s +$0.38 after Monday’s -$3.45),
  • BioNTech (BNTX +$1.88),
  • IQVA Holdings (IQV +$1.71 after Wednesday’s -$2.36 after Tuesday’s -$4.88 after Monday’s +$1.51),
  • CRISPR Therapeutics (CRSP +$1.63 after Wednesday’s -$1.35 after Tuesday’s +$1.07 after Monday’s +$2.21),
  • AxoGen (AXGN +$1.43),
  • Vericel (VCEL +$1.30 after Wednesday’s -$2.22 after Tuesday’s -$1.27 after Monday’s +$1.28),
  • Capricor Therapeutics (CAPR +$1.12 after Wednesday’s -$1,52 after Tuesday’s -$1.12),

Flat (3)

  • Rocket Therapeutics (RCKT)
  • Generation Bio (GBIO) – acquired
  • Harvard Apparatus RT (OTCQB: HRGN)

Thursday’s Closing DOWN (6 of 6): 

  • Supernus Therapeutics (SUPN -$0.55),
  • Lenz Therapeutics (LENZ -$0.09),
  • Ionis Pharmaceuticals (IONS -$0.07 after Wednesday’s +$3.04 after Monday’s -$0.45),
  • Brainstorm Cell Therapeutics (BCLI -$0.05),
  • Caribou Biosciences (CRBU -$0.04),
  • Sangamo Therapeutics (SGMO -$0.0136),

 

The Bottom Line: More of the … WHY and a lot of what ifs …

... Bubblelicious ???? .... 

The S&P 500 has risen more than 10% month to date, putting the index on pace for its best month since November 2020.

The Nasdaq is heading for a more than 15% jump, tracking for its best month since April 2020.

The Dow is set to end April with a more than 7% gain — its strongest monthly performance since November 2024.

Oil prices reversed course Thursday, with Brent crude futures losing 3.41% to close at $114.01 a barrel and West Texas Intermediate futures falling 1.69% to settle at $105.07.

 

April 5th Week:

  • 4/30 – Thursday closed positive with 31 incliners, 6 decliners and 3 flats
  • 4/29 - Wednesday closed negative with 5 incliners, 33 decliners and 2 flats
  • 4/28 – Tuesday closed negative with 17 incliners, 20 decliners and 3 flats
  • 4/27 - Monday closed negative with 13 incliners, 24 decliners and 3 flats

April 4th Week:

  • 4/24 – Friday closed negative with 11 incliners, 27 decliners and 2 flats
  • 4/23 - Thursday closed negative with 7 incliners, 30 decliners and 3 flats
  • 4/22 – Wednesday closed positive with 30 incliners, 9 decliners and 1 flat
  • 4/21 – Tuesday closed negative with 5 incliners, 33 decliners and 2 flats
  • 4/20 - Monday closed negative with 16 incliners, 21 decliners and 3 flats

 

Q1/26 Earnings Release Dates:

  • Moderna (MRNA) - Friday, 5/1
  • IQVIA Holdings (IQV), uniQure NV (QURE), Ultragenyx Pharmaceuticals (RARE) and Supernus Therapeutics (SUPN) – Tuesday, 5/5
  • Sarepta Therapeutics (SRPT) – Wednesday, 5/6
  • Vericel (VCEL) – Thursday, 5/7

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there – closed end funds” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

 

Why do I keep repeating, framed in a different para, so investors can make the connection

The top three (3) performing in the session:    Winners

  • Thursday: Alnylam Pharmaceuticals (ALNY), Vertex (VRTX) and uniQure NV (QURE)
  • Wednesday: Ionis Pharmaceuticals (IONS), Alnylam Pharmaceuticals (ALNY) and Mesoblast (MESO)
  • Tuesday: Vertex (VRTX), AxoGen (AXGN) and Beam Therapeutics (BEAM)
  • Monday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM)

The worst three (3) in the session: Losers’

  • Thursday: Supernus Therapeutics (SUPN), Lenz Therapeutics (LENZ) and Brainstorm Cell Therapeutics (BCLI)
  • Wednesday: Vertex (VRTX), Moderna (MRNA) and Vericel (VCEL)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), IQVA Holdings (IQV) and Arrowhead Pharmaceuticals (ARWR)
  • Monday: Vertex (VRTX), BioNTech (BNTX) and Compass Therapeutics (CMPX)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.